(Perakizumab)Biosimilar Reference Antibody-GS40541

货号：GS40541

Perakizumab (also known as RG4934) is a humanized IgG1‑kappa monoclonal antibody that specifically targets interleukin‑17A (IL‑17A), a key pro‑inflammatory cytokine. As an IgG1 isotype, it is designed to engage immune effector functions such as antibody‑dependent cellular cytotoxicity (ADCC). By binding with high affinity to IL‑17A, it prevents the cytokine from interacting with its receptor (IL‑17RA/IL‑17RC), thereby inhibiting downstream inflammatory signaling pathways (e.g., NF‑κB, MAPK) that drive tissue inflammation and damage. It is being developed as a potential therapeutic for IL‑17‑mediated autoimmune and inflammatory diseases, such as psoriasis, psoriatic arthritis, and axial spondyloarthritis.